Trials / Completed
CompletedNCT07252843
Integrating Clinical, Protein Expression, and Genetic Markers to Predict Lymphedema in Breast Cancer
Lymphedema Prediction Model in Breast Cancer After Axillary Lymph Node Dissection: A Study of Clinicopathological Factors, Receptor Expression (VEGFR3, TGFBR2), and Genetic Predisposition (GJA4, MET, GATA2)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 133 (actual)
- Sponsor
- Dharmais National Cancer Center Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational ambidirectional cohort study is to develop a prediction model to identify the risk of lymphedema after axillary lymph node dissection (ALND) in patients with breast cancer. The main questions it aims to answer are: * Can clinicopathological factors predict the development of lymphedema? * Do protein expression profiles and genetic mutations increase susceptibility to lymphedema? Participants will: * Undergo clinical evaluation and indocyanine green (ICG) lymphography to diagnose lymphedema. * Provide lymphatic tissue and blood samples during ALND surgery for immunohistochemical protein analysis and gene mutation assessment. * Be followed over time to monitor the onset and progression of lymphedema.
Conditions
Timeline
- Start date
- 2022-10-11
- Primary completion
- 2024-03-21
- Completion
- 2025-07-29
- First posted
- 2025-11-28
- Last updated
- 2025-11-28
Locations
1 site across 1 country: Indonesia
Source: ClinicalTrials.gov record NCT07252843. Inclusion in this directory is not an endorsement.